Suzetrigin: A Novel Pain Medication with Potential for the Swiss Market
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to severe acute pain in adults. It was developed by Vertex Pharmaceuticals and represents the first new class of pain medications in over two decades.
Suzetrigin works by selectively inhibiting the voltage-gated sodium channel NaV1.8, which is primarily expressed in peripheral pain-sensing neurons. By specifically blocking this channel, Suzetrigin modulates pain transmission without affecting the central nervous system, thereby avoiding the risk of dependence commonly associated with opioid-based pain medications.
In clinical trials, Suzetrigin demonstrated significant pain reduction compared to placebo but was not more effective than opioids. Common side effects include itching, muscle cramps, skin rash, and elevated creatine kinase levels.
Although Suzetrigin has already been approved in the United States, approval by the European Medicines Agency (EMA)—and thus in Switzerland—is still pending. Given the global efforts to find alternatives to opioid-based pain medications, Suzetrigin could play a significant role in the future of pain management.
The introduction of Suzetrigin in Switzerland would offer a new treatment option for patients with acute pain, particularly for those at risk of opioid dependence or for whom NSAIDs are contraindicated.
Suzetrigin represents a promising advancement in pharmacological pain management. Its novel mechanism of action and lack of dependence potential make it an attractive alternative to existing pain medications. Future approval in Switzerland could offer patients and healthcare providers a valuable new option for the treatment of acute pain.
However, it is important to note that the FDA approval is based on only two studies, both of which focus solely on its use for acute—not chronic—pain. Due to the limited number of cases studied, conclusions regarding its efficacy across different areas of pain management remain restricted.
Subscribe to Newsletter
We’d be happy to share more about us and our services in the next newsletter and on www.issz.ch.
Current Affairs
Further News & Publications
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Pulsed Radiofrequency Treatment (pRF)
Die gepulste Radiofrequenz-Behandlung (pRF) stellt eine minimalinvasive, nicht-destruktive Methode zur Behandlung
chronischer Schmerzen dar. Im Gegensatz zur thermischen Radiofrequenzablation, die durch Hitzeeinwirkung Nerven
1 year of Interventional Pain Medicine SZ AG – Less pain, more quality of life
On 3 May 2025, we celebrated the one-year anniversary of the Institute for Interventional Pain Medicine SZ AG – a significant milestone on our journey
Neuromodulation: Innovative Approaches to Chronic Pain
The term neuromodulation encompasses a variety of established therapeutic methods, including not only spinal epidural neurostimulation (Spinal Cord Stimulation – SCS), which is often used
Team – Dr. med. T. Tessmann #NewDoctor #NewPainSpecialist
From June, Dr. Tobias Tessmann will join ISSZ. He already worked as a resident in anesthesiology at Spital Lachen from 2019-2021 together with Dr. J.
Certification as an SSIPM Training Centre Pain Clinic B
We recently announced that we would apply for certification as an SSIPM training centre “Pain Clinic B”. We are now very pleased to have received
Cooperation with the Institute for Interventional Pain Medicine Zurich AG (IISZ)
Similar to the long-standing, close friendship and professional relationship between Jan Ludwigs and Daniel Friis, the connection between the ISSZ and the Institute for Interventional
Suzetrigin: A Novel Pain Medication in Switzerland
Suzetrigin (brand name: Journavx™) is an innovative, non-opioid analgesic that was approved in January 2025 by the U.S. FDA for the treatment of moderate to
Pulsed Radiofrequency Treatment (pRF)
Die gepulste Radiofrequenz-Behandlung (pRF) stellt eine minimalinvasive, nicht-destruktive Methode zur Behandlung
chronischer Schmerzen dar. Im Gegensatz zur thermischen Radiofrequenzablation, die durch Hitzeeinwirkung Nerven
1 year of Interventional Pain Medicine SZ AG – Less pain, more quality of life
On 3 May 2025, we celebrated the one-year anniversary of the Institute for Interventional Pain Medicine SZ AG – a significant milestone on our journey